progesterone
/ IBSA Institute Biochemical SA, Cedars-Sinai
- LARVOL DELTA
Home
Next
Prev
1 to 18
Of
18
Go to page
1
October 24, 2025
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3 | N=680 | Active, not recruiting | Sponsor: IBSA Institut Biochimique SA | Recruiting ➔ Active, not recruiting
Enrollment closed • Infertility • Sexual Disorders
April 07, 2025
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3 | N=680 | Recruiting | Sponsor: IBSA Institut Biochimique SA | Trial primary completion date: Aug 2025 ➔ Dec 2025
Trial primary completion date • Infertility • Sexual Disorders
September 23, 2024
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3 | N=680 | Recruiting | Sponsor: IBSA Institut Biochimique SA | Trial completion date: Mar 2025 ➔ Apr 2026 | Trial primary completion date: Sep 2024 ➔ Aug 2025
Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
March 05, 2024
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3 | N=680 | Recruiting | Sponsor: IBSA Institut Biochimique SA | Trial completion date: Sep 2024 ➔ Mar 2025 | Trial primary completion date: Feb 2024 ➔ Sep 2024
Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
March 04, 2024
SexVAP: Sexual Intercourse and Vaginal Absorption of Progesterone
(clinicaltrials.gov)
- P=N/A | N=40 | Completed | Sponsor: University Hospital, Montpellier | Recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Feb 2024
Trial completion • Trial completion date • Infertility • Sexual Disorders
July 13, 2023
Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females.
(PubMed, Clin Pharmacol Drug Dev)
- "Mild injection site reactions were reported with similar frequency for SC and IM progesterone. With further research, twice-daily SC progesterone may offer an alternative to existing available treatments for luteal phase support."
Journal
March 01, 2023
Prolutex in Frozen Embryo Transfer Cycles at the Blastocyst Stage (PROGEX)
(clinicaltrials.gov)
- P2 | N=213 | Completed | Sponsor: IBSA Institut Biochimique SA | Recruiting ➔ Completed | Trial completion date: Apr 2023 ➔ Dec 2022
Trial completion • Trial completion date • Infertility • Sexual Disorders
November 15, 2022
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3 | N=680 | Recruiting | Sponsor: IBSA Institut Biochimique SA | Not yet recruiting ➔ Recruiting | Trial completion date: May 2024 ➔ Sep 2024 | Trial primary completion date: Oct 2023 ➔ Feb 2024
Enrollment open • Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
August 03, 2022
Prolutex in Frozen Embryo Transfer Cycles at the Blastocyst Stage (PROGEX)
(clinicaltrials.gov)
- P2 | N=212 | Recruiting | Sponsor: IBSA Institut Biochimique SA | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Jan 2022 ➔ Dec 2022
Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
March 02, 2022
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3 | N=600 | Not yet recruiting | Sponsor: IBSA Institut Biochimique SA | Trial completion date: Apr 2023 ➔ May 2024 | Trial primary completion date: Jan 2023 ➔ Oct 2023
Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
August 25, 2021
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3; N=600; Not yet recruiting; Sponsor: IBSA Institut Biochimique SA; Trial completion date: Sep 2022 ➔ Apr 2023; Initiation date: Jun 2021 ➔ Jan 2022; Trial primary completion date: Jun 2022 ➔ Jan 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infertility • Sexual Disorders
August 25, 2021
Prolutex in Frozen Embryo Transfer Cycles at the Blastocyst Stage (PROGEX)
(clinicaltrials.gov)
- P2; N=212; Recruiting; Sponsor: IBSA Institut Biochimique SA; Trial completion date: Oct 2021 ➔ Apr 2022; Trial primary completion date: Jun 2021 ➔ Jan 2022
Clinical • Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
March 09, 2021
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3; N=600; Not yet recruiting; Sponsor: IBSA Institut Biochimique SA; Initiation date: Nov 2020 ➔ Jun 2021; Trial primary completion date: Mar 2022 ➔ Jun 2022
Clinical • Trial initiation date • Trial primary completion date • Infertility • Sexual Disorders
January 27, 2021
Progesterone for the Treatment of COVID-19 in Hospitalized Men
(clinicaltrials.gov)
- P1; N=40; Completed; Sponsor: Sara Ghandehari; Active, not recruiting ➔ Completed; Trial completion date: Apr 2021 ➔ Aug 2020
Clinical • Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 15, 2020
Progesterone for the Treatment of COVID-19 in Hospitalized Men
(clinicaltrials.gov)
- P1; N=40; Active, not recruiting; Sponsor: Sara Ghandehari; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease
September 15, 2020
PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
(clinicaltrials.gov)
- P3; N=600; Not yet recruiting; Sponsor: IBSA Institut Biochimique SA
Clinical • New P3 trial • Infertility • Sexual Disorders
August 08, 2020
Prolutex in Frozen Embryo Transfer Cycles at the Blastocyst Stage (PROGEX)
(clinicaltrials.gov)
- P2; N=212; Recruiting; Sponsor: IBSA Institut Biochimique SA; Trial completion date: Jan 2020 ➔ Oct 2021; Trial primary completion date: Oct 2019 ➔ Jun 2021
Clinical • Trial completion date • Trial primary completion date • Infertility • Long-acting Reversible Contraceptives • Sexual Disorders
May 07, 2020
Study examines progesterone to reduce inflammation in Covid-19
(Healio)
- "The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 among hospitalized men. This will be a randomized controlled trial enrolling 40 men with confirmed COVID-19....Half the men will receive standard care and half will receive 100 mg subcutaneous progesterone twice daily, in the abdomen or arm, for 5 days. Primary outcome is clinical status of participants at day 15....We will assess their clinical status after receiving the medication. We are looking at how they were when they started, and how they progressed on treatment....We presented this to FDA, and FDA allowed us to perform a clinical trial..."
Cytokine storm • New trial • Infectious Disease • Novel Coronavirus Disease
1 to 18
Of
18
Go to page
1